Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney ...

Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Other companies are also developing amylin-targeting drugs. Novo Nordisk’s amycretin targets both amylin and GLP-1. Viking Therapeutics, whose pipeline includes both injectable and oral agonists ...

Ascletis announces positive results from US phase Ia SAD study of small molecule oral GLP-1R agonist ASC30 in patients with obesity: Hong Kong, China Wednesday, January 22, 2025, ...

Oral delivery of drugs requires far higher quantities of ... its 12-week human study already underway in Australia (study GLP-1-H24-4). In that study arm, oral DehydraTECH-tirzepatide will be ...

Laxxon Medical reports positive results from pilot PK study of innovative oral GLP-1 agonist weight loss tablet, LXM.2 ...

Lexaria Bioscience (LEXX) announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study ...

s leading glucagon-like peptide-1 / glucose-dependent insulinotropic (GLP-1/GIP) drugs. Furthermore, the oral DehydraTECH-tirzepatide evidenced a comparable overall reduction in blood glucose from ...